论文部分内容阅读
目的探讨血脂康对急性冠脉综合征(ACS)患者血清高敏C-反应蛋白(hs-CRP)的影响。方法84例ACS患者随机分为常规治疗组和血脂康治疗组,后者在常规治疗基础上另予血脂康治疗,疗程共8周,另设健康对照组30例。于治疗前后分别检测血清hs-CRP水平,做治疗前后对比。结果两组ACS患者血清hs-CRP水平较健康对照组明显升高(P<0.01),治疗8周后,血脂康治疗组患者较常规治疗组hs-CRP、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)和载脂蛋白B(apoB)水平均有明显下降(P<0.05、0.01),高密度脂蛋白胆固醇(HDL-C)及载脂蛋白A(apoA)水明显升高(P<0.05)。结论血脂康能明显降低ACS血清hs-CRP水平,抑制斑块内炎症反应,从而稳定斑块,减少冠状动脉事件的发生。
Objective To investigate the effect of Xuezhikang on serum high sensitive C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS). Methods Eighty-four patients with ACS were randomly divided into routine treatment group and Xuezhikang treatment group. The latter was treated with Xuezhikang routinely on the basis of routine treatment. The course of treatment was 8 weeks, and another 30 healthy control subjects. Serum hs-CRP levels were measured before and after treatment, do contrast before and after treatment. Results Serum hs-CRP levels in ACS patients were significantly higher than those in healthy controls (P <0.01). After 8 weeks of treatment, the serum levels of hs-CRP, total cholesterol (TC), low density lipids (P <0.05, 0.01), HDL-C and apolipoprotein A (P <0.05) (apoA) water was significantly higher (P <0.05). Conclusion Xuezhikang can significantly reduce hs-CRP levels in ACS serum, inhibit the inflammatory reaction in plaque, stabilize the plaque and reduce the occurrence of coronary events.